This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

Curis Announces Abstracts For Its Partnered Programs, Erivedge(R) And Debio 0932 To Be Presented At The 2014 ASCO Annual Meeting

Stocks in this article: CRIS

LEXINGTON, Mass., May 23, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel, targeted drug candidates for the treatment of human cancers, today announced that its collaborators, Roche/Genentech and Debiopharm Group™ will present results from clinical studies of Erivedge ® and Debio 0932, respectively, at the 50 th Annual Meeting of American Society of Clinical Oncology (ASCO) to be held from May 30 th to June 3 rd in Chicago, IL.

Curis' collaborator, Roche/Genentech will present the following abstracts for Erivedge ®, a first-in-class hedgehog pathway inhibitor approved for the treatments of advanced basal cell carcinoma (BCC).

Erivedge Presentations:
Date/Time: Saturday, May 31, 2014, 8:00 AM - 11:45 AM
Abstract #: 9081
Presentation Title: Vismodegib for advanced basal cell carcinoma: duration of response after vismodegib discontinuation and response to vismodegib retreatment upon disease progression.
Presenter: Aleksandar Sekulic, MD, PhD
   
Date/Time:  Saturday, May 31, 2014, 8:00 AM - 11:45 AM
Abstract #: TPS9104
Presentation Title: A phase II study to assess vismodegib in the neoadjuvant treatment of locally advanced basal cell carcinoma (laBCC): The Vismodegib Neoadjuvant (VISMONEO) study.
Presenter: Laurent Mortier, MD, PhD
   
Date/Time:  Saturday, May 31, 2014, 8:00 AM - 11:45 AM
Abstract #: TPS9116^
Presentation Title: A phase II, single-armed, multicenter trial of neoadjuvant vismodegib in patients with large and/or recurrent basal cell carcinoma: NICCI. 
Presenter: Ulrike Leiter, MD
   
Date/Time:  Saturday, May 31, 2014, 8:00 AM - 11:45 AM
Abstract #: TPS9121
Presentation Title: MIKIE: A randomized, double-blind, regimen-controlled, phase II, multicenter study to assess the efficacy and safety of two different vismodegib regimens in patients with multiple basal cell carcinomas.
Presenter: Rainer Kunstfeld
   
Date/Time:  Monday, June 2, 2014, 8:00 AM - 11:00 AM
Abstract #: 9012
Presentation Title: Vismodegib in the treatment of patients with metastatic basal cell carcinoma (mBCC) and distant metastases: Survival in the pivotal phase II and phase I studies.
Presenter: Karl D. Lewis, MD
   
Date/Time:  Monday, June 2, 2014, 8:00 AM - 11:00 AM
Abstract #: 9013
Presentation Title: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: Final update (30-month) of the pivotal ERIVANCE BCC study.
Presenter: Aleksandar Sekulic, MD, PhD

Curis' licensee, Debiopharm will present the following abstracts for Debio 0932, an oral HSP90 inhibitor being investigated in clinical trials for non-small cell lung cancer and renal cell carcinoma.

Debio 0932 Presentations:
Date/Time:  Sunday, June 1, 2014, 8:00 AM - 11:45 AM
Abstract #: 2550^
Presentation Title: Final results from the phase I study expansion cohort of Debio 0932, an oral HSP90 inhibitor, in patients with solid tumors. 
Presenter: Pierre Fumoleau, MD
   
Date/Time:  Sunday, June 1, 2014, 8:00 AM - 11:45 AM
Abstract #: TPS2632^
Presentation Title: The HALO study: A phase I-II of the oral HSP90 inhibitor Debio 0932 in combination with SOC in first- and second-line therapy of advanced NSCLC.
Presenter: Jesus Corral Jaime, MD

Additional information on the presentations can be found below and abstracts can be accessed at  www.asco.org .

About Curis, Inc.

Curis is an oncology-focused drug development company seeking to develop novel drug candidates for the treatment of human cancers. Curis is seeking to further the development of its pipeline of proprietary targeted cancer drug candidates, including CUDC-907, a dual HDAC and PI3K inhibitor and CUDC-427, a small molecule antagonist of IAP proteins. Erivedge® is our most advanced asset and the first and only FDA-approved medicine for the treatment of advanced basal cell carcinoma and is being commercialized and developed by Roche and Genentech, a member of the Roche Group, under a collaboration agreement between Curis and Genentech.  Curis-discovered HSP90 inhibitor, Debio 0932, is being studied in patients with advanced lung and kidney cancers by its partner Debiopharm. For more information, visit Curis' website at www.curis.com .  

CONTACT: For More Information:
         Mani Mohindru, Ph.D.
         Vice President, Corporate Strategy and Investor Relations
         Curis, Inc.
         617-503-6605
         mmohindru@curis.com
         
         Michael P. Gray
         Chief Financial and Chief Business Officer
         Curis, Inc.
         617-503-6632
         mgray@curis.com

Curis, Inc. Logo

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,810.06 +91.06 0.51%
S&P 500 2,063.50 +10.75 0.52%
NASDAQ 4,712.97 +11.1030 0.24%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs